Rubitecan: SUPG completed enrollment of 3 Phase III trials of rubitecan in >1,800 patients with pancreatic cancer. Included in the studies are patients refracto

SuperGen Inc. (SUPG), Dublin, Calif. Product: Rubitecan Business: Cancer Therapeutic category: Cell proliferation Target: Topoisomerase I Description: Oral 9-nitrocamptothecin topoisomerase I inhibi...